Stock 300725 PHARMABLOCK SCIENCES (NANJING), INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials PharmaBlock Sciences (Nanjing), Inc.

Equities

300725

CNE1000035K5

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-19 pm EDT 		5-day change 1st Jan Change
33.23 CNY +1.03% Intraday chart for PharmaBlock Sciences (Nanjing), Inc. -2.18% -15.38%
Apr. 24 PharmaBlock Proposes Final Dividend for 2023 CI
Apr. 23 PharmaBlock Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9,893 20,042 28,391 16,073 7,841 6,607 - -
Enterprise Value (EV) 1 9,893 20,042 28,391 16,073 7,841 6,607 6,607 6,607
P/E ratio 65.1 x 109 x 58.3 x 51.3 x 39.7 x 28.2 x 19.1 x 16.9 x
Yield 0.22% - 0.07% 0.12% 0.79% 0.36% 0.45% -
Capitalization / Revenue 14.9 x 19.6 x 23.6 x 10.1 x 4.54 x 3.32 x 2.74 x 2.35 x
EV / Revenue 14.9 x 19.6 x 23.6 x 10.1 x 4.54 x 3.32 x 2.74 x 2.35 x
EV / EBITDA 53.2 x 91 x 51.6 x 39.9 x 25.8 x 14.5 x 12.2 x 9.72 x
EV / FCF - - -106,125,368 x - - - - -
FCF Yield - - -0% - - - - -
Price to Book 13.4 x 10.6 x 11.7 x 6.35 x 2.9 x 2.22 x 1.96 x 1.82 x
Nbr of stocks (in thousands) 188,227 188,799 199,700 199,664 199,665 198,829 - -
Reference price 2 52.56 106.2 142.2 80.50 39.27 33.23 33.23 33.23
Announcement Date 2/28/20 3/25/21 4/28/22 4/21/23 4/23/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 662.2 1,022 1,202 1,595 1,725 1,990 2,410 2,817
EBITDA 1 186 220.3 550 402.9 304.4 454.7 542.7 680
EBIT 1 162 194.1 493 296.7 184.6 242 352.7 388
Operating Margin 24.46% 18.99% 41.02% 18.61% 10.7% 12.16% 14.63% 13.77%
Earnings before Tax (EBT) 1 170.8 204.5 507.8 323.3 221.4 264.5 370 447
Net income 1 149.7 184.2 486.6 314.2 197.4 235.5 347 393
Net margin 22.6% 18.02% 40.49% 19.7% 11.44% 11.84% 14.4% 13.95%
EPS 2 0.8077 0.9769 2.440 1.570 0.9900 1.180 1.737 1.970
Free Cash Flow - - -267.5 - - - - -
FCF margin - - -22.26% - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 0.1154 - 0.1000 0.1000 0.3100 0.1200 0.1500 -
Announcement Date 2/28/20 3/25/21 4/28/22 4/21/23 4/23/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - -268 - - - - -
ROE (net income / shareholders' equity) 22.9% 21.8% 22.6% 12.4% 7.16% 7.85% 10.2% 10.5%
ROA (Net income/ Total Assets) 17% - 16.4% 7.51% - 4.7% 5.9% -
Assets 1 881.1 - 2,966 4,185 - 5,011 5,881 -
Book Value Per Share 2 3.940 10.00 12.20 12.70 13.60 15.00 17.00 18.20
Cash Flow per Share 2 0.6700 1.440 1.190 1.240 1.240 2.370 2.210 1.850
Capex 1 173 75.2 506 558 314 310 310 -
Capex / Sales 26.16% 7.35% 42.07% 34.97% 18.18% 15.58% 12.86% -
Announcement Date 2/28/20 3/25/21 4/28/22 4/21/23 4/23/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for PharmaBlock Sciences (Nanjing), Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
33.23 CNY
Average target price
40 CNY
Spread / Average Target
+20.37%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
PHARMABLOCK SCIENCES (NANJING), INC. Stock PharmaBlock Sciences (Nanjing), Inc.
-15.38% 913M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+34.35% 705B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.55% 583B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.49% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.15% 332B
ABBVIE INC. Stock AbbVie Inc.
+6.19% 291B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 238B
ROCHE HOLDING AG Stock Roche Holding AG
-3.15% 210B
NOVARTIS AG Stock Novartis AG
+10.50% 209B
AMGEN INC. Stock Amgen Inc.
+9.21% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300725 Stock
  4. Financials PharmaBlock Sciences (Nanjing), Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW